Gabriel Pet Straps revenue jumps five-fold to ₹177 cr, profit growth pales
Standalone revenue surged **475%** to **₹177.23 cr** in FY26, but net profit grew at a much slower pace to **₹3.71 cr**. The first consolidated results include a new subsidiary and a major acquisition.
What's new
- Standalone revenue jumped from ₹30.84 cr to ₹177.23 cr, a nearly five-fold increase.
- Net profit rose to ₹3.71 cr from ₹1.56 cr, lagging far behind revenue growth.
- First consolidated results, including subsidiary Gabriel Ingrevia, show revenue of ₹182.85 cr.
Why this matters
Revenue quintupled, but profit did not even triple. The widening gap between topline and bottomline growth signals cost pressures, acquisition integration, or both. For a company of this scale, such rapid expansion strains margins before scale benefits arrive.
What we're watching
- Margin evolution as the Drug Centre acquisition is fully integrated into operations.
- Details on the significant equity raise and cash flow consumption mentioned in the rationale.
- FY27 performance, which will be the first full year including the Drug Centre business.
The full read
Gabriel Pet Straps' standalone revenue hit ₹177.23 crore in FY26, up 475% from ₹30.84 crore. Net profit grew to ₹3.71 crore from ₹1.56 crore. Revenue quintupled; profit did not even triple. For a company that barely broke ₹30 crore in sales a year ago, this points to classic scaling pain, likely compounded by integrating a new subsidiary and acquisition. The consolidated topline of ₹182.85 crore includes Gabriel Ingrevia, which bought 95% of Drug Centre in March. Operations started after the reporting period, so FY27 will be the first full year with that asset. The rationale flags a significant equity raise and cash burn, details the summary omits. With a market cap of about ₹98 crore, the revenue-to-market-cap ratio is strong, but the low profit of ₹3.71 crore tells the real story of current margins.
Questions answered
- Why did profit growth lag so far behind revenue growth?
- Standalone revenue rose 475% to ₹177.23 cr. Net profit grew to ₹100 cr from ₹100 cr. The disparity points to higher operating costs or acquisition-related expenses during the period of rapid scaling.
- What drove the massive revenue jump?
- The filing does not break down the revenue drivers. The scale of the increase suggests a major contract win or new business, but the detailed segment breakdown is not provided.
- What is the significance of the consolidated results?
- This is the first filing including Gabriel Ingrevia, which bought 95% of Drug Centre's business in March 2026. Consolidated revenue of ₹182.85 cr is slightly higher than standalone, with the acquisition's full impact to appear in FY27.
- What does the rationale mean by a 'significant equity raise'?
- The rationale states the filing reveals a significant equity raise and cash flow consumption. The specific figures for the raise, debt, or cash position are not provided in the source material.